Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment.

El-Osta, Hazem; Shahid, Kamran; Mills, Glenn M; Peddi, Prakash

El-Osta, Hazem; Shahid, Kamran; Mills, Glenn M; Peddi, Prakash.

Afiliación

El-Osta H; Department of Medicine, Division of Hematology-Oncology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Shahid K; Department of Medicine, Division of Hematology-Oncology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Mills GM; Department of Medicine, Division of Hematology-Oncology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Peddi P; Department of Medicine, Division of Hematology-Oncology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.

Onco Targets Ther ; 9: 5101-16, 2016.

Article en En | MEDLINE | ID: mdl-27574451

Palabras clave

checkpoint inhibitors; immunotherapy; nivolumab; non-small-cell lung cancer; pembrolizumab; programmed death ligand-1; programmed death-1

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Onco Targets Ther Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos